Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure in Patients Before Cataract Surgery.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.
详细描述
The literature shows that the effectiveness of mannitol in decreasing intraocular pressure (IOP) varies widely. Although it rapidly lowers IOP in the majority of people, clinical results and the extent of the reduction differ depending on a number of factors. Mannitol can be detrimental for patients with pulmonary edema or severe heart failure (congestive heart failure) because it quickly draws fluid into the bloodstream, increasing intravascular volume. In addition to contributing to the local literature, the results of this study will aid in determining the true efficacy and safety of mannitol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of any gender
- •Aged 30-80 years
- •Undergoing cataract surgery
排除标准
- •Patients with glaucoma, uveitis, or corneal pathology
- •With trauma
- •Previously had surgery
- •With exfoliation syndrome
- •Had iridotomies
- •Had use of sympathetic α1 antagonist
研究组 & 干预措施
Group-A
After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.
干预措施: Mannitol (Drug)
Group-B
After employing standard protocol for dilatation, patients were given a placebo.
干预措施: Placebo (Drug)
研究者
Muhammad Aamir Latif
Research Consultant
RESnTEC, Institute of Research